These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 25110417)

  • 1. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
    Jeong WJ; Cha PH; Choi KY
    World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.
    Tardito S; Matis S; Zocchi MR; Benelli R; Poggi A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
    Lièvre A; Ouine B; Canet J; Cartier A; Amar Y; Cacheux W; Mariani O; Guimbaud R; Selves J; Lecomte T; Guyetant S; Bieche I; Berger F; de Koning L
    Br J Cancer; 2017 Dec; 117(12):1819-1827. PubMed ID: 29024937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
    De Cuyper A; Van Den Eynde M; Machiels JP
    Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution.
    Khan K; Valeri N; Dearman C; Rao S; Watkins D; Starling N; Chau I; Cunningham D
    Crit Rev Oncol Hematol; 2019 Nov; 143():153-163. PubMed ID: 31678702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
    Miyamoto Y; Suyama K; Baba H
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
    Normanno N; Tejpar S; Morgillo F; De Luca A; Van Cutsem E; Ciardiello F
    Nat Rev Clin Oncol; 2009 Sep; 6(9):519-27. PubMed ID: 19636327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
    Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.
    De Stefano A; Carlomagno C
    World J Gastroenterol; 2014 Aug; 20(29):9732-43. PubMed ID: 25110411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to EGFR-targeted therapies in colorectal cancer.
    Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A
    Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
    Dienstmann R; De Dosso S; Felip E; Tabernero J
    Mol Oncol; 2012 Feb; 6(1):15-26. PubMed ID: 22189054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
    Sartore-Bianchi A; Bencardino K; Di Nicolantonio F; Pozzi F; Funaioli C; Gambi V; Arena S; Martini M; Lamba S; Cassingena A; Schiavo R; Bardelli A; Siena S
    Target Oncol; 2010 Mar; 5(1):19-28. PubMed ID: 20383783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.
    de Mello RA; Marques AM; Araújo A
    World J Gastroenterol; 2013 Oct; 19(38):6315-8. PubMed ID: 24151349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
    Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
    J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
    Montagut C; Argilés G; Ciardiello F; Poulsen TT; Dienstmann R; Kragh M; Kopetz S; Lindsted T; Ding C; Vidal J; Clausell-Tormos J; Siravegna G; Sánchez-Martín FJ; Koefoed K; Pedersen MW; Grandal MM; Dvorkin M; Wyrwicz L; Rovira A; Cubillo A; Salazar R; Desseigne F; Nadal C; Albanell J; Zagonel V; Siena S; Fumi G; Rospo G; Nadler P; Horak ID; Bardelli A; Tabernero J
    JAMA Oncol; 2018 Apr; 4(4):e175245. PubMed ID: 29423521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.